| Autor: |
Amjad AI; Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA., Ali H; Division of General Internal Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA., Appleman LJ; Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA., Maranchie J; Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA., Jackman S; Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA., Parwani A; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA., Dhir R; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA., Roy S; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA., Parikh RA; Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA. |
| Abstrakt: |
Renal medullary carcinoma (RMC) is a rare but aggressive malignancy affecting young individuals with sickle cell trait. Renal medullary carcinoma commonly presents with advanced or metastatic disease and is associated with a rapidly progressive clinical course and an extremely short overall survival measured in weeks to few months. Due to the rarity of RMC, there is no proven effective therapy and patients are often treated with platinum-based chemotherapy. We report near-complete radiological and pathological response in a patient treated with dose-dense MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy. The patient underwent consolidation nephrectomy and retroperitoneal lymph node dissection and had a 16-month progression-free survival, one of the longest reported in patients with RMC. |
